Business Wire

LIXIL-FOUNDATION

28.10.2016 07:02:53 CEST | Business Wire | Press release

Share
"The 6th LIXIL International Student Architectural Competition"; Top Prize-winning Royal Danish Academy of Fine Arts' INFINITE FIELD is Completed

The LIXIL Foundation (located in Koto-ku, Tokyo; Chairman: Yoko Ushioda), which facilitates surveys and research related to the housing and building materials industries as well as supporting the development of human resources, is pleased to announce today that the next-generation sustainable housing “INFINITE FIELD” designed by The Royal Danish Academy of Fine Arts (Denmark) has been completed on a site of Memu Meadows in Taiki-cho Hokkaido, environmental technology research facilities managed by the foundation.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161027007034/en/

INFINITE FIELD is the top prize winner in the 6th LIXIL International Student Architectural Competition sponsored by the LIXIL Foundation, aimed to seek and review next-generation sustainable housing technology and communicate that technology to the global community. The project was designed based on the theme: “Comfort and Lightness.” For the first time in its history, this year’s competition called for proposals for a light shelter that can be easily assembled and moved.

INFINITE FIELD is a structure that features a 360-degree timber platform and the design enveloped by soft, permeable membranes. From this elevated platform, which is aligned with an average snow depth in this region, users are able to enjoy the view of snowfield spreading infinitely during the winter months while the platform transforms into a place to cool off in the summer heat. It is designed to allow people to feel changes of the seasons in Taiki-cho.

The varied textile membranes invite nature in and allow the architecture in itself to move. The fabric is layered to create the space; these textiles are chosen with consideration of various environmental properties to ensure a comfortable thermal environment. Dwellers can operate these layered membranes on their own, adding or removing them to adjust their relationships with the environment while they serve as an expanded threshold.

With the completion of INFINITE FIELD, Memu Meadows is now a home to six structures designed by students. The effects of these “next-generation sustainable houses” will continue to be verified.

Accompanying Material

-- INFINITE FIELD designed by The Danish Royal Academy of Fine Arts (Denmark)

Supervisor:

Anders Brix, Professor            

Students:

Kazumasa Takada/Bas Spaanderman
Scarlett Emma Hessian/Jesse Thomas
Benjamin Hock Yuu Tan/Konstantinos Fetsis

Design Supervisor: Kengo Kuma & Associates

 

Structural Engineer: Oak Structural Design

General Contractor: Takahashi Construction Company

Building Area: 21.3m2

Construction Cost: Approx. 15 million yen

Construction Period: August 2016 - October 2016

 

[Features]

  • Seasonal Transformation
    INFINITE FIELD was imagined as a permeable experience, one where users are able to dictate their conditions, while engaging with the natural environment surrounding them. During the winter months it is from this elevated vantage point that users are aligned with an infinite sea of snow, and are treated to overlook the landscape from the warmth of the nest. In the summer heat the platform transforms into a place for rest and quiet reflection, looking out to a field of wild grasses, trees and bright blue skies. This 360-degree timber base is a contemplative oasis providing panoramic views of the natural surrounding.
  • Spatial Tactility
    INFINITE FIELD is an architecture of change and graduation, allowing users to experience and enjoy the shifting environment in comfort, while simultaneously enhancing our human connection with nature. A set of soft, permeable membranes made of varied textiles invites nature in and allows the design to move and breathe with the seasons. As you transition across the platform users can operate the membranes, moving them to add or remove barriers between the environment and themselves. These layers are an expanded threshold, an envelope inviting nature in while allowing a tactile interaction with the architecture.
  • Material Dwelling
    The fabric architecture imparts a whole new perspective to familiar scenes. Silk fabric blades hang from the draped inner membrane disrupting heat and air flow. Users are able to visually perceive the gentle winds and air that flow through the dwelling as these fabric blades gently sway and flutter in the breeze. The project’s textiles are chosen with consideration of the various environmental properties, while their layered design provides adaptable thermal zones for user’s personal comfort.

-- Overview of Facility
Name: Memu Meadows
Location: 158-1 Memu, Taiki-cho, Hiro-gun, Obihiro, Hokkaido
Owner: LIXIL Foundation 2-1-1 Ojima, Koto-ku, Tokyo, 136-8535
Site area: App. 184,000 square meters
Main facilities: Experimental house “Même”, “Mock-up of Multiple floor Bamboo House”, “A recipe to live”, “BARN HOUSE”, “HORIZON HOUSE”, “NEST WE GROW”, “INVERTED HOUSE”, Multipurpose Facility, Conference Pavilion, Residence 1L and 1R (accommodation for researchers), two log houses (accommodation for researchers), fitness center, restaurant, Administration Wing, etc.
Official website: http://www.lixiljsfound.com/

Contact:

LIXIL Foundation
Kenji Iida, +81-3-5626-1008
2-1-1, Oshima, Koto-ku, Tokyo 136-8535
Fax: +81-3-5626-1033
LIXIL Foundation website: http://www.lixiljsfound.com/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye